Orbital aspergillosis: Voriconazole - The new standard treatment?

19Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background/Aim: To describe a case of invasive orbital aspergillosis and evaluate treatments and outcomes. Methods: A case report and review of orbital aspergillosis treatment with voriconazole in the English language literature. Conclusion: Amphotericin B with debridement is the current standard of care for orbital aspergillosis; however, its prognosis is unfavorable. When compared to amphotericin B, voriconazole demonstrates a survival benefit, has less systemic toxicity, and is better tolerated by patients. While a prospective trial comparing amphotericin B to voriconazole in orbital aspergillosis is not feasible, there is evidence to support the use of voriconazole as primary therapy. Copyright © 2012 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Ohlstein, D. H., Hooten, C., Perez, J., Clark, C. L., & Samy, H. (2012, January). Orbital aspergillosis: Voriconazole - The new standard treatment? Case Reports in Ophthalmology. https://doi.org/10.1159/000336276

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free